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1. Introduction
Infective endocarditis (IE) is a rare but potentially fatal condition. Almost always 
it is caused by bacteria, even though fungal endocarditis may occur. The infectious 
agent enters the bloodstream where it may adhere to the endocardium and predomi-
nantly the cardiac valves. While infective endocarditis (IE) may occur in any person, 
some risk factors are well known. Among these, the most significant are patients with 
valvular anomalies, prosthetic valves, cardiac implantable electric devices (CIEDs), 
and intravenous drug users. The clinical presentation may vary greatly depending on 
factors pertaining to the host as well as the causative microbe. Initial symptoms may 
be low-grade and unspecific but occasionally fulminant and severe. The diagnosis is 
often challenging and based on a combination of several clinical, microbiological, and 
radiological findings. The cornerstone of treatment is high-dose antibiotics, which are 
generally administered intravenously. However, pharmaceutical treatment alone is 
sometimes insufficient, and surgical intervention is required. This is particularly true 
in complicated cases, as well as in prosthetic valve endocarditis and CIED infection.
2. Epidemiology, pathophysiology, and prophylaxis
Bacteremia is a prerequisite for the development of infective endocarditis [1], 
and it is a more common phenomenon than might be assumed. In fact, transient 
bacteremia often occurs in various dental and surgical procedures, as well as in 
toothbrushing, flossing, and even chewing [2]. Despite the ubiquity of transient 
bacteremia, infective endocarditis is a rare condition with annual incidence in the 
USA varying between 11 and 15 cases per 100,000 population in the first 12 years 
of the new millennium [3]. It can thus be surmised that bacteremia alone is insuffi-
cient to cause the condition. Data from animal models suggest that the development 
of IE is dependent on the existence of a valvular lesion, which may be symptomatic, 
previously unknown or even microscopic, and clinically insignificant. The lesion in 
turn allows bacteria to adhere to the endocardial surface, promoting the establish-
ment of the principal lesion in infective endocarditis: the vegetation [4].
The degree of valvular damage that is sufficient to cause disease varies greatly 
depending on the causative agent. Staphylococcus aureus has an exceptional status in 
this regard, owing to its recognized tendency to cause IE in patients without a pre-
existing valvular condition. Infectious material in the bloodstream causes an upregu-
lation of the body’s inflammatory response. Fractions of the vegetation may come 
loose and cause embolization of other organs. Additionally, the presence of a vegeta-
tion on the endocardial surface may contribute irreversible structural damage [3].
The topic of antibiotic prophylaxis to prevent IE is a subject of controversy. As 
described above, transient bacteremia is very common in the general population, 
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while manifest infective endocarditis is rare. Concordantly, striving to administer 
antibiotics to all individuals at risk for transient bacteremia would be a futile 
endeavor. Indications for prophylaxis in surgical and dental procedures have varied 
over the years, but it has never been proven that general prophylaxis is indicated, 
regardless of whether the procedure is high or low risk. Current recommendations, 
as put forward by the European Society of Cardiology, assert that antibiotic pro-
phylaxis only be considered in high-risk procedures in patients with a pre-existing 
heart condition that confers a heightened risk of endocarditis. These include 
prosthetic valve, cyanotic congenital heart disease, and patients with a previous 
episode of IE. Antibiotic prophylaxis is not recommended in other forms of valvular 
or congenital heart disease [5].
3. Clinical symptoms, diagnosis, and imaging
Infective endocarditis is a condition whose presentation may vary greatly, 
which consequently may make the diagnosis elusive, conferring a significant delay 
in initiation of treatment. The presenting symptoms stem from several distinct 
pathophysiological mechanisms, and any combination of these may occur in any 
given individual:
• Symptoms of disseminated infection
• Symptoms of structural cardiac damage
Definite infective endocarditis
Pathologic criteria
1. Microorganisms demonstrated by culture or histologic examination of a vegetation, a vegetation that 
has embolized, or an intracardiac abscess specimen
2. Pathologic lesions; vegetation or intracardiac abscess confirmed by histologic examination
Showing active endocarditis
Clinical criteria
1. Two major criteria
2. One major criterion and three minor criteria
3. Five minor criteria
Possible infective endocarditis
1. One major criterion and one minor criterion
2. Three minor criteria
Rejected
1. Firm alternate diagnosis explaining evidence of infective endocarditis
2. Resolution of infective endocarditis syndrome with antibiotic therapy for < 4 days
3. No pathologic evidence of infective endocarditis at surgery or autopsy, with antibiotic therapy for 
<4 days
4. Does not meet criteria for possible infective endocarditis, as above
Table 1. 
Modified Duke criteria [6].
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• Symptoms of an upregulated immune system and circulating immune 
complexes
• Symptoms of septic embolism to distant organs
These mechanisms are reflected in the diagnostic criteria (the Duke criteria) 
provided in Table 1 [6]. To accurately make an IE diagnosis, it is crucial to (a) per-
form a thorough clinical examination, (b) acquire adequate microbiological sam-
ples, and (c) ensure that correct radiological imaging is carried out. As to the latter, 
the cornerstone of radiological imaging has long been echocardiography: preferably 
with a transesophageal approach. Other modalities, such as ECG-triggered com-
puterized tomography and positron emission tomography, are sometimes used in 
clinical practice, but are as yet not included in the Duke criteria [5].
4. Microbiology, antibiotic treatment, and surgery
The most common etiologic agents in IE are Gram-positive bacteria, which are 
responsible for more than 90% of cases. IE caused by Gram-negative bacteria and 
fungi does occur but rarely. While traditionally the major bacterial finding has been 
streptococcal species, later decades have seen a continuing rise of S. aureus [3].
Regardless of etiology, treatment consists of a long course of high-dose antibiot-
ics, which are generally administered intravenously for the entire duration. Length 
of the treatment is usually 2–4 weeks but may be longer in complicated cases—par-
ticularly in those involving foreign material in the bloodstream. Due to the high 
total drug exposure, it is imperative to use pharmaceuticals which are well tolerated 
by the majority of patients. As in other severe infections, antibiotics of the beta-
lactamase class are preferred when applicable. These drugs are distinguished by a 
combination of high efficacy and good tolerability [7].
Pharmaceutical treatment alone is often insufficient, however. Thoracic surgery 
is required in 25–50% of cases during acute infection and 20–40% during conva-
lescence. Surgery is effective (a) as a means of source control (b) in preventing 
embolization and (c) as a means to repair structural cardiac damage [8]. Procedural 
risk is significant, however, and the decision to operate should be taken on an 
individual basis and in collaboration with representatives of appropriate clinical 
and diagnostic specialties. To this end it is recommended that decisions are taken by 
a unit known as the endocarditis team [9].
5. Conclusion
The aim of this book is to provide a deepened understanding of infective endo-
carditis which is a complex condition. Due to its diverse clinical features, patients 
with infective endocarditis may present at any part of the healthcare system, and 
awareness is crucial in order to establish a rapid and accurate diagnosis. In order to 
prevent mortality, as well as morbidity arising from embolic events and structural 
cardiac damage, it is important that appropriate medical and surgical management 
be initiated promptly in each individual case.
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